Dynavax GmbH manufactures pharmaceutical products using gene- and biotechnology methods and specializes in the development and production of vaccines. Its focus is on hepatitis B vaccines; Dynavax produces the recombinant HBsAg antigen needed for Heplisav-B and performs extensive quality control analyses. The company acts as the marketing authorization holder in Europe and operates solely as a manufacturing site; it is a 100% subsidiary of Dynavax Technologies Corporation (Emeryville, USA). In the 2024 fiscal year Dynavax generated revenues of EUR 30,900,658.57 and employed on average 146 staff.
Die Entwicklung, Herstellung und der Vertrieb neuer biotechnologischer Prozesse und Produkte.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Düsseldorf Local Court, HRB 20023 (as of 7 October 2026)
Source: German Commercial Register (Handelsregister) Düsseldorf Local Court, HRB 20023 (as of 7 October 2026)
Sign in to download data
Source: German Commercial Register (Handelsregister) Düsseldorf Local Court, HRB 20023 (as of 7 October 2026)
AstraZeneca Computational Pathology GmbH
München · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin
Eurofins Genomics Europe Pharma and Diagnostics Products & Services Sanger/PCR GmbH
Ebersberg · Forschung und Entwicklung im Bereich Biotechnologie
Bio-Circle Surface Technology GmbH
Gütersloh · Forschung und Entwicklung im Bereich Biotechnologie
Sign in to view detailed salary and cost trends.
